Patents by Inventor Jonathan Belk
Jonathan Belk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12365736Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments, the ALK7-binding proteins inhibit or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.Type: GrantFiled: May 29, 2020Date of Patent: July 22, 2025Assignee: Acceleron Pharma Inc.Inventors: John Knopf, Ravindra Kumar, Asya Grinberg, Dianne Sako, Roselyne Castonguay, Yossi Dagon, Jonathan Belk, Nathan J. Sharkey
-
Patent number: 12337035Abstract: Provided are antibodies, fragments thereof, chimeric antigen receptors (CARs) and T cell receptors (TCRs) comprising one or more of the dual TACI-BCMA binding domains disclosed herein. Provided are compositions, cells and cell therapies comprising the same. Further provided are methods of treatment.Type: GrantFiled: March 25, 2022Date of Patent: June 24, 2025Assignee: Kite Pharma, Inc.Inventors: Jonathan Belk, Eugene Bolotin, Raghavender Chivukula, Matthew Drever, Edward Hai Dhow Liao
-
Publication number: 20250145707Abstract: Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.Type: ApplicationFiled: December 31, 2024Publication date: May 8, 2025Inventors: Arianne Perez, Stuart A. Sievers, Ruben Alvarez Rodriguez, Jonathan Belk, Jed Wiltzius
-
Publication number: 20250059258Abstract: The present disclosure relates to the field of chromatography, and more specifically to novel affinity ligands and affinity agents which are suitable for use in isolation of antibody and antibody fragments that contain the heavy chain first constant region (CHI). The disclosure encompasses affinity ligands as such, chromatography separation matrices (affinity agents) comprising an affinity ligand according to the disclosure, and a process of isolating antibodies, especially IgGs, and CHI-containing antibody fragments thereof using an affinity ligand according to the disclosure. Methods of making the affinity ligands and separation matrices are also provided.Type: ApplicationFiled: December 23, 2022Publication date: February 20, 2025Applicant: AVITIDE LLCInventors: Thomas Scanlon, Jonathan Belk, Kelley Kearns, Sarah Valentini
-
Publication number: 20240374671Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize, ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.Type: ApplicationFiled: June 11, 2024Publication date: November 14, 2024Inventors: Ravindra Kumar, Jonathan Belk, Asya Grinberg, Dianne Sako, Roselyne Castonguay
-
Publication number: 20240287196Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented, or ameliorated by targeting ALK7.Type: ApplicationFiled: March 22, 2024Publication date: August 29, 2024Inventors: Ravindra Kumar, Roselyne Castonguay, Dianne Sako, Jonathan Belk, Nathan J. Sharkey
-
Patent number: 12042524Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated musle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.Type: GrantFiled: April 15, 2021Date of Patent: July 23, 2024Assignee: Acceleron Pharma Inc.Inventors: Ravindra Kumar, Jonathan Belk, Asya Grinberg, Dianne Sako, Roselyne Castonguay
-
Publication number: 20240236347Abstract: Aspects of the disclosure provide methods and apparatuses for video encoding/decoding. In some examples, an apparatus for video decoding includes receiving circuitry and processing circuitry. The processing circuitry decodes prediction information of a current block from a coded video bitstream. In some embodiments, the processing circuitry determines a first subpartition and a second sub-partition of the current block based on the decoded prediction information, and then reconstructs the first sub-partition and the second sub-partition of the current block based on at least a neighboring sample of the current block that is out of a neighboring area of at least one of the first sub-partition and the second sub-partition.Type: ApplicationFiled: February 22, 2022Publication date: July 11, 2024Inventors: Christian Ndong, Jonathan Belk, Sarah Mallon, Kelley Kearns, Thomas Scanlon, Warren Kett
-
Patent number: 11981738Abstract: The disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments, the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, obesity, type 2 diabetes, and their associated conditions, metabolic disorders, and other diseases or conditions that can be treated by targeting ALK7.Type: GrantFiled: October 25, 2018Date of Patent: May 14, 2024Assignee: Acceleron Pharma Inc.Inventors: Ravindra Kumar, Roselyne Castonguay, Dianne Sako, Jonathan Belk, Nathan J. Sharkey
-
Publication number: 20240150468Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.Type: ApplicationFiled: October 6, 2023Publication date: May 9, 2024Applicant: Checkpoint Therapeutics, Inc.Inventors: Jonathan BELK, Nathan J. SHARKEY, Leonid GORELIK
-
Publication number: 20240137538Abstract: Aspects of the disclosure provide methods and apparatuses for video encoding/decoding. In some examples, an apparatus for video decoding includes receiving circuitry and processing circuitry. The processing circuitry decodes prediction information of a current block from a coded video bitstream. In some embodiments, the processing circuitry determines a first subpartition and a second sub-partition of the current block based on the decoded prediction information, and then reconstructs the first sub-partition and the second sub-partition of the current block based on at least a neighboring sample of the current block that is out of a neighboring area of at least one of the first sub-partition and the second sub-partition.Type: ApplicationFiled: February 22, 2022Publication date: April 25, 2024Inventors: Christian Ndong, Jonathan Belk, Sarah Mallon, Kelley Kearns, Thomas Scanlon, Warren Kett
-
Publication number: 20240115611Abstract: Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.Type: ApplicationFiled: September 20, 2023Publication date: April 11, 2024Inventors: Arianne Perez, Stuart A. Sievers, Ruben Alvarez Rodriguez, Jonathan Belk, Jed Wiltzius
-
Publication number: 20230416379Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.Type: ApplicationFiled: June 20, 2023Publication date: December 28, 2023Inventors: John Knopf, Jonathan Belk, Nathan J. Sharkey, Ravindra Kumar, Asya Grinberg, Dianne Sako, Roselyne Castonguay, Yossi Dagon
-
Patent number: 11834505Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.Type: GrantFiled: March 13, 2020Date of Patent: December 5, 2023Assignee: Checkpoint Therapeutics, Inc.Inventors: Jonathan Belk, Nathan J. Sharkey, Leonid Gorelik
-
Patent number: 11793834Abstract: Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.Type: GrantFiled: December 11, 2019Date of Patent: October 24, 2023Assignee: Kite Pharma, Inc.Inventors: Arianne Perez, Stuart A. Sievers, Ruben Alvarez Rodriguez, Jonathan Belk, Jed Wiltzius
-
Patent number: 11708414Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.Type: GrantFiled: June 17, 2021Date of Patent: July 25, 2023Assignee: Acceleron Pharma Inc.Inventors: John Knopf, Jonathan Belk, Nathan J. Sharkey, Ravindra Kumar, Asya Grinberg, Dianne Sako, Roselyne Castonguay, Yossi Dagon
-
Publication number: 20230146195Abstract: The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.Type: ApplicationFiled: November 14, 2022Publication date: May 11, 2023Inventors: Jed WILTZIUS, Ruben ALVAREZ RODRIGUEZ, Jonathan BELK
-
Publication number: 20230037815Abstract: Provided herein are anti-CD 19 antibodies and multi-specific binding proteins that bind CD 19, CD3, and serum albumin. Also provided are pharmaceutical compositions comprising these antibodies or multi-specific binding proteins, expression vectors and host cells for making these antibodies or multi-specific binding proteins, and methods of use of these antibodies or multi-specific binding proteins in treating cancers.Type: ApplicationFiled: December 11, 2020Publication date: February 9, 2023Inventors: Patrick A. Baeuerle, Jennifer Michaelson, Bochong Li, Naveen Mehta, Jonathan Belk, Nathan Sharkey, Bianka Prinz, Bradley M. Lunde, Nga Rewa Houston
-
Patent number: 11505613Abstract: The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.Type: GrantFiled: September 12, 2019Date of Patent: November 22, 2022Assignee: Kite Pharma, Inc.Inventors: Jed Wiltzius, Ruben Alvarez Rodriguez, Jonathan Belk
-
Publication number: 20220354892Abstract: Provided are antibodies, fragments thereof, chimeric antigen receptors (CARs) and T cell receptors (TCRs) comprising one or more of the dual TACI-BCMA binding domains disclosed herein. Provided are compositions, cells and cell therapies comprising the same. Further provided are methods of treatment.Type: ApplicationFiled: March 25, 2022Publication date: November 10, 2022Inventors: Jonathan Belk, Raghavender Chivukula, Matthew Drever, Edward Hai Dhow Liao